Krishna Gundabolu, MD
Assistant Professor, Internal Medicine
Division of Hematology & Oncology
Academic Office mailing address:
UNMC Hematology/Oncology Division
986840 Nebraska Medical Center
Omaha, NE 68198-6840
Main Academic Ph. 402-559-8500
New Patient Referral Ph. 402-559-5600
Fred & Pamela Buffett Cancer Center
505 South 45th Street
Omaha, NE 68105 (map)
Nebraska Medicine Village Pointe
111 N. 175th St.
Omaha, NE, 68118 (map)
Medical School: Guntur Medical College, Guntur, India 1997-2003
Medical Officer/Resident Cornwall Regional Hospital, Department of Health, Jamaica 2004-2005
Internal Medicine Residency, Jacobi Medical Center, Bronx, NY 2006-2009
Hematology/Oncology Fellowship, Montefiore Medical Center, Bronx, NY, 2009-2012
Fellowship in Blood and Marrow Stem Cell Transplantation, Mayo Clinic, Rochester, 2012-2013
Clinical Translational Research Mentored Scholars Program, University of Nebraska Medical Center, Omaha NE
Myeloid malignancies, Benign hematology with focus on various bleeding and clotting disorders,
Allogeneic Hematopoietic Cell Transplantation
Dr. Krishna Gundabolu is an Assistant Professor in the Department of Internal Medicine, Division of Hematology/Oncology at the University of Nebraska Medical Center. He received his medical degree from Guntur Medical College, NTR University of Health Sciences, Andhra Pradesh, India in October 2003. He worked as a senior medical resident at Cornwall Regional Medical Center in Jamaica, WI (2004-2005). He did his Internal Medicine residency at Jacobi Medical Center/Albert Einstein College of Medicine (AECOM), Bronx, NY from 2006-2009 when he was awarded the best senior resident of the graduating class of 2009. He did his fellowship in Hematology-Oncology at Montefiore Medical Center/AECOM, Bronx, NY from 2009-2012 and then did fellowship in Blood and Bone Marrow Stem Cell Transplantation at Mayo Clinic, Rochester from 2012-2013. He worked as an Associate Consultant in the Department of Internal Medicine at Mayo Clinic, Rochester until he moved to Nebraska Medicine.
During his residency and fellowship he worked in the laboratory of Dr. Verma exploring mechanisms leading to Myeloid Stem Cell disorders and currently he is a member of National Comprehensive Cancer Network, Myeloproliferative Neoplasms panel. He authored or coauthored in multiple peer-reviewed publications, abstracts and book chapters. He is currently involved in clinical research related to myeloid malignancies, benign hematology, allogeneic hematopoietic stem cell transplantation, bleeding disorders and clotting disorders with an emphasis on thrombosis and bleeding disorders in cancer patients.
Stein BL, Gotlib J, Arcasoy M, Nguyen MH, Shah N, Moliterno A, Jamieson C, Pollyea DA, Scott B, Wadleigh M, Levine R, Komrokji R, Klisovic R, Gundabolu K, Kropf P, Wetzler M, Oh ST, Ribeiro R, Paschal R, Mohan S, Podoltsev N, Prchal J, Talpaz M, Snyder D, Verstovsek S, Mesa RA. Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. J Natl Compr Canc Netw. 2015 Apr;13(4):424-34.
Gundabolu K. The different faces of disseminated intravascular coagulation in solid tumors: how to identify and manage. Oncology (Williston Park). 2015 Feb;29(2):104, 106-7
Sridharan A, Jain R, Bachhuber MA, Yu Y, Ramesh Kh, Gundabolu K, Friedman EW, Verma AK. Epidemiologic study of myelodysplastic syndromes in a multiethnic, inner city cohort. Exp Hematol Oncol. 2014 Aug 23;3:22.
Hu CY, Mohtat D, Yu Y, Ko YA, Shenoy N, Bhattacharya S, Izquierdo MC, Park AS, Giricz O, Vallumsetla N, Gundabolu K, Ware K, Bhagat TD, Suzuki M, Pullman J, Liu XS, Greally JM, Susztak K, Verma A. Kidney cancer is characterized by aberrant methylation of tissue-specific enhancers that are prognostic for overall survival. Clin Cancer Res. 2014 Aug 15;20(16):4349-60.
Msaouel P, Lam AP, Gundabolu K, Chrysofakis G, Yu Y, Mantzaris I, Friedman E, Verma A. Abnormal platelet count is an independent predictor of mortality in the elderly and is influenced by ethnicity. Haematologica. 2014 May;99(5):930-6.
Lam AP, Gundabolu K, Sridharan A, Jain R, Msaouel P, Chrysofakis G, Yu Y, Friedman E, Price E, Schrier S, Verma AK. Multiplicative interaction between mean corpuscular volume and red cell distribution width in predicting mortality of elderly patients with and without anemia. Am J Hematol. 2013 Nov;88(11):E245-9. doi: 10.1002/ajh.23529. Epub 2013 Sep 9.
Heuck CJ, Mehta J, Bhagat T, Gundabolu K, Yu Y, Khan S, Chrysofakis G, Schinke C, Tariman J, Vickrey E, Pulliam N, Nischal S, Zhou L, Bhattacharyya S, Meagher R, Hu C, Maqbool S, Suzuki M, Parekh S, Reu F, Steidl U, Greally J, Verma A, Singhal SB. Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis. J Immunol. 2013 Mar 15;190(6):2966-75.
Bhagat TD, Zhou L, Sokol L, Kessel R, Caceres G, Gundabolu K, Tamari R, Gordon S, Mantzaris I, Jodlowski T, Yu Y, Jing X, Polineni R, Bhatia K, Pellagatti A, Boultwood J, Kambhampati S, Steidl U, Stein C, Ju W, Liu G, Kenny P, List A, Bitzer M, Verma A. miR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling. Blood. 2013 Apr 11;121(15):2875-81.
Zhou L, McMahon C, Bhagat T, Alencar C, Yu Y, Fazzari M, Sohal D, Heuck C, Gundabolu K, Ng C, Mo Y, Shen W, Wickrema A, Kong G, Friedman E, Sokol L, Mantzaris I, Pellagatti A, Boultwood J, Platanias LC, Steidl U, Yan L, Yingling JM, Lahn MM, List A, Bitzer M, Verma A. Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase. Cancer Res. 2011 Feb 1;71(3):955-63.
Zhou L, Nguyen AN, Sohal D, Ying Ma J, Pahanish P, Gundabolu K, Hayman J, Chubak A, Mo Y, Bhagat TD, Das B, Kapoun AM, Navas TA, Parmar S, Kambhampati S, Pellagatti A, Braunchweig I, Zhang Y, Wickrema A, Medicherla S, Boultwood J, Platanias LC, Higgins LS, List AF, Bitzer M, Verma A. Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. Blood. 2008 Oct 15;112(8):3434-43.
Additional Publications at PubMed.Gov: https://www.ncbi.nlm.nih.gov/pubmed